Laboratory of Experimental Dermatology, Department of Dermatology, University Hospital and Health Campus Immunology Infectiology and Inflammation (GC-I3), Otto-von-Guericke-University, Magdeburg, Germany.
Laboratory of Experimental Dermatology, Department of Dermatology, University Hospital and Health Campus Immunology Infectiology and Inflammation (GC-I3), Otto-von-Guericke-University, Magdeburg, Germany.
Immunity. 2024 Oct 8;57(10):2260-2262. doi: 10.1016/j.immuni.2024.09.012.
Understanding the factors that lead to the therapeutic success of adoptive cell therapies using tumor-infiltrating lymphocytes (TIL-ACT) will improve current treatment protocols. In this issue of Immunity, Chiffelle et al. comprehensively compare the dynamics of CD8 T cell clonotypes during the course of ACT between responding and non-responding patients.
了解导致浸润肿瘤淋巴细胞（TIL-ACT）过继细胞疗法治疗成功的因素，将改进当前的治疗方案。在本期《免疫》杂志中，Chiffelle 等人综合比较了应答者和无应答者患者在 ACT 过程中 CD8 T 细胞克隆型的动态变化。
